Axsome Therapeutics vs Immunovant
Axsome Therapeutics (AXSM), health care, and Immunovant (IMVT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Axsome Therapeutics is worth $7.2B on the stock market and Immunovant $6.9B: Axsome Therapeutics is valued at 4% more. Over the past year Axsome Therapeutics's share price has moved -7.10% and Immunovant's +40.5%.
Key facts
- Axsome Therapeutics market value
- $7.2B
- Immunovant market value
- $6.9B
- Axsome Therapeutics revenue
- $638.5MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Axsome Therapeutics | Immunovant |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $7.2Bhigher | $6.9Blower |
| Revenue | $638.5M | — |
| Earnings | -$183.2Mhigher | -$505.6Mlower |
| Employees | 1,390higher | 315lower |
| Total assets | $689.8Mlower | $957Mhigher |
| Valuation | ||
| P/E | — | — |
| P/S | 11.2 | — |
| P/B | 67.8higher | 10.5lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -26.1% | — |
| Balance sheet | ||
| Net assets | $88.3Mlower | $852.6Mhigher |
| Total liabilities | $601.5Mhigher | $104.4Mlower |
| Total debt | $187.7M | — |
| Cash on hand | $322.9Mlower | $902.1Mhigher |
| Price change | ||
| Today | -0.77%lower | -0.21%higher |
| 1 year | -7.10%lower | +40.5%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Axsome Therapeutics only (0)
None of the tracked investors.
Immunovant only (3)
- Andrew Spokes1.1%
- Julian and Felix Baker1.0%
- David Einhorn0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns AXSM · Who owns IMVT
More on Axsome Therapeutics
Further comparisons
Axsome Therapeutics against its closest peers
Immunovant against its closest peers
Learn
Questions and answers
Which is bigger, Axsome Therapeutics or Immunovant?
By market value, Axsome Therapeutics is the larger: $7.2B against $6.9B for Immunovant.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Axsome Therapeutics and Immunovant?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Axsome Therapeutics and 3 hold Immunovant.
Cite this page
Funkfolio, “Axsome Therapeutics vs Immunovant”, data as of 18 November 2026. https://funkfolio.com/compare/axsm-vs-imvt
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.